investment in Synphaet Phatthanakan Hospital Project 01/11/2022 17:01 The acquisition of investment in Nan-Ram Co.,Ltd.'s remainder shares and status change 17/06/2022 12:42 The acquisition of investment in
ended as of September 30, 2021, which can be summarized as follows: 1) Profit & Loss Analysis : Q3 2021 (3 Months) (Unit : Million Baht unless otherwise stated) Q3 2021 Q3 2020 Change Amount % Change
operating expenses in Q1–2024 changed in line with and similar to the increase or decrease in revenue compared to Q1–2023. That is to say, the change rate in revenue for Q1–2024 increased by 29.9% and the
10.199% filed a letter requesting the company to hold extraordinary shareholders? meeting to consider the matters of (1) rights offering of newly issued shares and share warrants and (2) change of the
SUMMARY EXECUTIVE SUMMARY 2 2017 2018 % change Q3’2018 Q4’2018 % change million Baht million Baht y-on-y million Baht million Baht q-on-q Sales and service income 31,482 36,585 16.2% 9,691 9,933 2.5% EBITDA
63.1% of NNP. ABBREVIATION & OUR PROJECTSFINANCIAL PERFORMANCE FINANCIAL POSITION PROGRESS OF PROJECTS UNDER CONSTRUCTION EXECUTIVE SUMMARY EXECUTIVE SUMMARY 2 6M’2017 6M’2018 % change Q1’2018 Q2’2018
EXECUTIVE SUMMARY EXECUTIVE SUMMARY 2 6M’18 6M’19 change Q2’18 Q1’19 Q2’19 change change Btmn Btmn y-on-y Btmn Btmn Btmn y-on-y q-on-q Sales and service income 16,961 21,123 24.5% 8,805 10,257 10,866 23.4
granted a license from China Food and Drug Administration (CFDA) during the beginning of 2018 as the Company had to redesign and adjust product packaging according to the granted license as well as change
Consolidated financial statements Change Increase/(Decrease) For Three Months Period Ended 30 September 2017 2018 THB mm % THB mm % THB mm % Sale Revenue Revenue from selling product under Company’s trademark 1
for project development of not more than Baht 15,000 million will result in the total transaction value of not more than Baht 29,500 million, equivalent to the highest transaction size of 71.81 percent